Nanox Imaging Ltd. (NASDAQ: NNOX) has taken a significant step in broadening its international reach by signing an exclusive sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its AI-powered bone health solution, HealthOST, in the United Kingdom. The agreement, announced by Nanox's subsidiary Nanox AI Ltd., grants Vertec exclusive rights to market and resell HealthOST in the UK for an initial three-year term, subject to minimum annual license commitments.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes routine CT scans to help clinicians evaluate and assess musculoskeletal diseases of the spine, including osteoporosis. This innovative technology is designed to support opportunistic detection of vertebral fragility fractures, a condition often underdiagnosed. The significance of this partnership is underscored by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in November 2025, which endorsed HealthOST and its predecessor, HealthVCF, as one of five AI technologies for use within the National Health Service (NHS) to aid in the opportunistic detection of vertebral fragility fractures.
The NICE recommendation is a critical milestone that validates the clinical utility of HealthOST and paves the way for its adoption across the NHS. By leveraging Vertec Scientific's established distribution network and expertise in the UK medical device market, Nanox aims to accelerate the deployment of HealthOST in NHS trusts, potentially improving patient outcomes through earlier detection and management of osteoporosis and related fractures. Osteoporosis is a major public health concern, particularly among the aging population, and early identification is crucial for preventing debilitating fractures.
This strategic move aligns with Nanox's broader mission to drive the world's transition to preventive healthcare by delivering an integrated medical imaging and healthcare services platform. The company combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, remote radiology access, and health IT solutions to enable earlier detection and improved clinical efficiency. HealthOST is a key component of Nanox.AI, a suite of AI algorithms that augment the interpretation of routine CT imaging to identify early signs of chronic disease.
The UK represents a substantial market opportunity for Nanox, especially with the NHS's increasing focus on integrating AI-driven diagnostic tools to enhance efficiency and patient care. The exclusive partnership with Vertec Scientific is expected to drive revenue growth through recurring license fees, contributing to Nanox's overall financial performance. Additionally, this agreement strengthens Nanox's presence in Europe, following the CE marking of HealthOST, and sets the stage for potential expansions into other markets.
For Nanox, this deal is not just about commercial expansion; it underscores the company's commitment to making preventive healthcare accessible and affordable. By enabling opportunistic screening for osteoporosis during routine CT scans, HealthOST has the potential to identify at-risk patients who might otherwise go undiagnosed until a fracture occurs. This proactive approach aligns with global healthcare trends toward value-based care and population health management.
In conclusion, the exclusive UK reseller agreement with Vertec Scientific marks a pivotal development for Nanox Imaging, leveraging NICE's endorsement to penetrate the NHS market. As the company continues to innovate and expand its AI-driven solutions, this partnership could serve as a model for future collaborations in other regions, ultimately contributing to improved bone health outcomes and reduced healthcare costs.
